Press release
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Severe Asthma Therapeutics Market Size, Share & Trends Analysis Report By Therapy Class (Biologics, Small Molecule / Targeted Immunomodulators, Optimized Inhaled Add-on Therapies, Systemic Corticosteroids (Maintenance), Interventional Therapies), By Drug Target / Mechanism (Anti-IgE, Anti-IL-5, Anti-IL-5 Receptor (IL-5Rα), Anti-IL-4 / IL-13 Pathway (IL-4Rα), Anti-TSLP, Anti-IL-33 / ST2 Axis, Anti-OX40 / OX40L, Intracellular Signaling Modulators (JAK, STAT, others)), By Phenotype / Endotype (Severe Eosinophilic Asthma, Severe Allergic Asthma, Type-2 High Severe Asthma, Type-2 Low / Non-Eosinophilic Severe Asthma, Oral Corticosteroid-Dependent Severe Asthma), By Route of Administration (Subcutaneous, Intravenous, Inhaled, Oral), By Patient Age Group (Pediatric (6-11 Years), Adolescent (12-17 Years), Adult (18-64 Years), Geriatric (65+ Years)), By End User (Hospitals, Specialty Clinics (Pulmonology / Allergy), Ambulatory Care Centers),-Market Outlook And Industry Analysis 2035"
Severe Asthma Therapeutics Market Size is predicted to grow at a 6.9% CAGR during the forecast period for 2026 to 2035.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3433
The Severe Asthma Therapeutics Market recognizes the increasing requirement for innovative treatment solutions for patients with severe, treatment-refractory asthma who remain uncontrolled despite optimized standard therapy. Severe asthma is a heterogeneous, immune-driven chronic respiratory disease characterized by persistent symptoms, frequent exacerbations, and substantial impact on quality of life, while accounting for a disproportionate burden of asthma-related healthcare resource utilization.
Severe asthma therapeutics comprise targeted biologics, monoclonal antibodies, small molecule immunomodulators, and optimized add-on therapies aimed at modulating pivotal inflammatory pathways, decreasing exacerbations, enhancing lung function, and preventing chronic reliance on systemic corticosteroids. These treatments are increasingly used in phenotype-driven and biomarker-guided approaches in specialty respiratory care environments.
The market's growth is fueled by increasing awareness of asthma heterogeneity, enhanced diagnosis of severe asthma phenotypes, and excellent clinical performance of targeted therapies, especially biologics. Increasing regulatory approvals, enhanced physician confidence in precision medicine, and advances in immunology have also fueled the market. Nonetheless, the market's growth is hindered by the high cost of advanced therapies, limitations in reimbursement in some areas, and difficulties in precise patient identification. In addition, the lengthy treatment duration and need for specialized administration and monitoring have also hindered accessibility despite the excellent clinical performance.
List of Prominent Players in the Severe Asthma Therapeutics Market:
• AB Science
• AER Therapeutics
• Amgen
• Apogee Therapeutics
• Areteia Therapeutics
• AstraZeneca
• Bio-Thera Solutions
• Biosion
• CSPC ZhongQi Pharmaceutical Technology
• Generate:Biomedicines
• GlaxoSmithKline (GSK)
• Incyte
• Insmed
• Kinaset Therapeutics
• Kymera Therapeutics
• Lanier Biotherapeutics
• Novartis
• Oneness Biotech
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• Suzhou Connect Biopharmaceuticals
• Teva Pharmaceutical Industries
• Upstream Bio
Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com
Market Dynamics:
Drivers:
Key drivers of the Severe Asthma Therapeutics Market include the rising incidence of severe and uncontrolled asthma, driven by increasing environmental pollution, urbanization, and lifestyle-related risk factors. The swift adoption of targeted biologic therapies has been a key driver, as these therapies offer significantly better efficacy by targeting specific inflammatory mechanisms and enabling personalized, phenotype-driven therapy.
Furthermore, progress in biomarker-driven diagnostics and precision medicine, increasing regulatory approvals, and rising awareness among healthcare professionals and patients have all contributed to the earlier diagnosis and treatment of severe asthma, thus fueling the market growth.
Challenges:
The key challenges in the Severe Asthma Therapeutics Market are the high price of innovative biologic therapies, which restricts accessibility and adoption, especially in emerging and sensitive markets. The diagnosis of the condition and the identification of the patient phenotype are also challenging, thereby hindering the early start of therapy. Other factors are the long-term management of the condition, the need for administration by specialists, and monitoring for safety and efficacy, which increase the treatment burden and may therefore act as a hindrance to widespread market adoption.
Regional Trends:
The Severe Asthma Therapeutics Market is being led by north america. The dominance of the region is due to the high prevalence of severe asthma, well-developed healthcare infrastructure, and early adoption of innovative biologic therapies. Favorable reimbursement policies, easy access to specialty care, and physician familiarity with the concept of precision medicine have contributed to the swift adoption of targeted therapies. Moreover, the presence of large pharmaceutical firms, active clinical research, and rapid approval of new therapies have further strengthened the position of North America as the largest market.
Unlock Your Customization Options: https://www.insightaceanalytic.com/customization/3433
Key Development
• December 2025: GSK plc received FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older, supported by SWIFT-1 and SWIFT-2 Phase III trials showing 48-58% reductions in annualized asthma exacerbations with twice-yearly dosing versus placebo.
Segmentation of Severe Asthma Therapeutics Market -
By Therapy Class -
• Biologics
• Small Molecule / Targeted Immunomodulators
• Optimized Inhaled Add-on Therapies
• Systemic Corticosteroids (Maintenance)
• Interventional Therapies
By Drug Target / Mechanism -
• Anti-IgE
• Anti-IL-5
• Anti-IL-5 Receptor (IL-5Rα)
• Anti-IL-4 / IL-13 Pathway (IL-4Rα)
• Anti-TSLP
• Anti-IL-33 / ST2 Axis
• Anti-OX40 / OX40L
• Intracellular Signaling Modulators (JAK, STAT, others)
By Phenotype / Endotype -
• Severe Eosinophilic Asthma
• Severe Allergic Asthma
• Type-2 High Severe Asthma
• Type-2 Low / Non-Eosinophilic Severe Asthma
• Oral Corticosteroid-Dependent Severe Asthma
By Route of Administration-
• Subcutaneous
• Intravenous
• Inhaled
• Oral
By Patient Age Group-
• Pediatric (6-11 Years)
• Adolescent (12-17 Years)
• Adult (18-64 Years)
• Geriatric (65+ Years)
By End-user-
• Hospitals
• Specialty Clinics (Pulmonology / Allergy)
• Ambulatory Care Centers
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/severe-asthma-therapeutics-products-market/3433
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
[email protected]
This release was published on openPR.
